We wish to report an adverse effect of frequent administration of anthracycline cytotoxic drugs, affecting both nails and the palmar and plantar skin. Case 1 J.K., a 70-year-old woman, presented with liver metastases from a carcinoma of uncertain origin. She received chemotherapy including doxorubicin (Adriamycin) at a dose of 20mg per square metre per week (36mg weekly), as a bolus. After 5 weeks she developed painful erythema of the palms and soles, which was followed by desquamation at these sites. On withdrawal of the doxorubicin the skin of both areas returned to normal over the next 2 weeks.
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Case 2 V.C., a 66-year-old woman received epirubicin (Pharmorubicin) as a bolus dose of 40 mg per square metre per week, for granulosa cell carcinoma of the ovary. After 3 weeks she developed painful desquamation of the plantar skin, with loosening and opacity of both the finger and toe nails. On withdrawal of epirubicin the skin changes returned to normal over the course of one month. (Lokich, 1984; Vogelzang, 1985) . Onycholysis was recently reported as a consequence of chemotherapy, including anthracyclines in three patients (Cunningham et al., 1985) . All three, however, had biochemical evidence of zinc deficiency which may have been a contributory factor. Mitozantrone has also been implicated as causing onycholysis in two patients on single agent therapy for carcinoma of the breast (Speechley-Dick et al., 1988) . In none of these cases was the palmar or plantar skin involved.
We report skin changes involving the hands and feet, with or without onycholysis, in patients receiving frequent lowdose intermittent anthracycline therapy. While this is clearly not a life-threatening toxic effect, it may still be the cause of sufficient discomfort to require withdrawal of these agents.
